It has already reassigned some members of the DeepMind project, while others have already left the company.
The award-winning team behind Google DeepMind’s AlphaFold program is no more, according to Financial Times. Google has reassigned most of the team’s key members and the original authors of its papers, while a few others have already left the company. AlphaFold is an AI program that can accurately predict three-dimensional structures of proteins from their amino acid sequences in minutes instead of years. It’s now being used to accelerate drug discovery, develop vaccines and understand the structural changes in proteins associated with neurodegenerative diseases like Alzheimer’s and Parkinson’s.
DeepMind started developing AlphaFold in 2018. In 2020, it was recognized as a solution to humanity’s 50-year-old “protein folding problem,” which sought to answer how amino acids automatically fold into complex 3D shapes. Those shapes determine the biological role of a protein. Scientists had identified the structures of roughly 170,000 proteins over the past 50 years, using tools and techniques like X-ray and nuclear magnetic resonance. The AlphaFold team took information from those previous work and then fed it to their AI to train AlphaFold.
In 2021, Nature published the papers with AlphaFold’s methodology and the structure predictions of the entire human proteome, or the complete set of proteins expressed by our species. DeepMind then launched the AlphaFold Protein Structure Database, giving researchers free access to over 200 million protein structure predictions. In 2024, DeepMind CEO Demis Hassabis and John Jumper, who was a staff research scientist when the project began and who eventually became a VP and engineering fellow, won the Nobel Prize in Chemistry for their work on AlphaFold.
Jumper announced in June that he was leaving DeepMind to join Anthropic. A couple of his colleagues jumped ship to Anthropic, as well. DeepMind has confirmed to the Times that it also moved staff members internally to Gemini-focused projects. Other former staff members were reassigned to Alphabet’s drug-discovery company Isomorphic Labs, which is a DeepMind spin-off.
As the Times notes, this represents Google’s decision to put more and more of its resources into developing Gemini. “Our strategy over the last nine years has been to focus on grand challenges… a concrete goal every project is focused on,” said Pushmeet Kohli, the VP of research at Google DeepMind. “The strategy has evolved.”
